{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:06:06Z","timestamp":1784797566900,"version":"3.55.0"},"reference-count":7,"publisher":"SAABRON PRESS","issue":"1","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.46989\/001c.92586","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T16:21:20Z","timestamp":1706718080000},"source":"Crossref","is-referenced-by-count":0,"title":["Considerations for the treatment of frail multiple myeloma patients"],"prefix":"10.46989","volume":"6","author":[{"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[{"name":"Sorbonne University, Service d'H\u00e9matologie Clinique Et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, INSERM UMRs938, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/s1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Thierry Facon","year":"2021","journal-title":"The Lancet Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1470-2045","issn-type":"print"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Robert A. Kyle","year":"2003","journal-title":"Mayo Clinic Proceedings","ISSN":"https:\/\/id.crossref.org\/issn\/0025-6196","issn-type":"print"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review","volume":"13","author":"Hira Mian","year":"2023","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"issue":"10068","key":"ref4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s0140-6736(16)31594-x","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Brian G M Durie","year":"2017","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"10","key":"ref5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/nejmoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Lotfi Benboubker","year":"2014","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"Suppl 1","key":"ref6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"Utkarsh Goel","year":"2022","journal-title":"American Journal of Hematology","ISSN":"https:\/\/id.crossref.org\/issn\/0361-8609","issn-type":"print"},{"issue":"2-3","key":"ref7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s44228-023-00036-8","article-title":"Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)","volume":"5","author":"Nizar J. Bahlis","year":"2023","journal-title":"Clinical Hematology International","ISSN":"https:\/\/id.crossref.org\/issn\/2590-0048","issn-type":"print"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/92586-considerations-for-the-treatment-of-frail-multiple-myeloma-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:45:48Z","timestamp":1784796348000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/92586-considerations-for-the-treatment-of-frail-multiple-myeloma-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.92586","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}